• J Camuset, J M Naccache, X Dhalluin, M Febvre, F Wallyn, O Ouennoure, M-C Copin, J Assouad, M Antoine, J Cadranel, and C Fournier.
• Service de chirurgie thoracique, hôpital Tenon, CHU, AP-HP, 4, rue de la Chine, 75020 Paris, France. Electronic address: juliette.camuset@aphp.fr.
• Rev Mal Respir. 2019 Apr 1; 36 (4): 455-460.

IntroductionIn the diagnostic approach to interstitial lung disease (ILD), the use of transbronchial cryobiopsy (TBC) may offer an alternative to surgical lung biopsy (SLB). We report the diagnostic effectiveness and the safety of TBC in ILD based on the preliminary experience in two French university centers.MethodsTwenty four patients underwent TBC for the diagnosis of ILD in the operating room between 2014 and 2017. All the histological diagnoses obtained were then reviewed and validated during multidisciplinary discussions (MDD).ResultsPatients had an average of 3 TBC.TBC samples were analyzable in 22/24 (91.7%) patients. In these, samples allowed a histological diagnosis to be made in 14/22 (63.6%) patients and a diagnosis with certainty in 13/22 (59%) after MDD. The overall diagnostic yield from TBC was 13/24 (54.2%). Nine (37.5%) patients had a pneumothorax. Five (20.8%) patients had a bleeding. There were no deaths. Taking into account a possible initial learning curve and considering only the 15 patients who had their TBC after 2015, we note that a diagnosis could be made after MDD for 12 of them, that is, 80%.ConclusionA prospective randomized study is needed to evaluate the technique in France in order to specify its diagnostic performance and its safety profile in comparison to SLB.Copyright © 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.

42 keywords...

hide…